Cyclooxygenase-2 Is Essential for HER2/neu to Suppress N-(4-Hydroxyphenyl)retinamide Apoptotic Effects in Breast Cancer Cells

Cancer Research

Volumn 64, Issue 4, 2004, Pages 1224-1228

  Simeone, Ann Marie ^a   Li, Yu Jiang ^a   Broemeling, Lyle D ^a   Johnson, Marcella M ^a   Tuna, Musaffe ^a   Tari, Ana M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; FENRETINIDE; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NITRIC OXIDE; PROSTAGLANDIN E2; PROTEIN KINASE B; TRASTUZUMAB;

APOPTOSIS; ARTICLE; BREAST CANCER; BREAST TUMOR; CANCER CELL; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DRUG SENSITIVITY; ENZYME INHIBITION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; ONCOGENE NEU; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DINOPROST; FEMALE; FENRETINIDE; HUMANS; ISOENZYMES; MEMBRANE PROTEINS; NITRIC OXIDE; NITROBENZENES; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, ERBB-2; SULFONAMIDES;

EID: 1242316181     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-03-2188     Document Type: Article

References (19)

1. Kaptain, S., Tan, L. K., and Chen, B. Her-2/neu and breast cancer. Diagn. Mol. Pathol., 10: 139-152, 2001.
2. Simeone, A., Broemeling, L. D., Rosenblum, J., and Tari, A. M. HER2/neu reduces the apoptotic effects of N-(4-hydroxyphenyl)retinamide (4-HPR) in breast cancer cells by decreasing nitric oxide production. Oncogene, 22: 6739-6747, 2003.
3. Clark, A. S., West, K., Streicher, S., and Dennis, P. A. Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol. Cancer Ther., 1: 707-717, 2002.
4. Singh, B., and Lucci, A. Role of cyclooxygenase-2 in breast cancer. J. Surg. Res., 108: 173-179, 2002.
5. Subbaramaiah, K., Norton, L., Gerald, W., and Dannenberg, A. J. Cyclooxygenase-2 is overexpressed in HER-2/neu-positive breast cancer. J. Biol. Chem., 277: 18649-18657, 2002.
6. Von Knethen, A., and Brune, B. Cyclooxygenase-2: an essential regulator of NO-mediated apoptosis. FASEB J., 11: 887-895, 1997.
7. Sun, Y., Tang, X. M., Half, E., Kuo, M. T., and Sinicrope, F. A. Cyclooxygenase-2 overexpression reduces the apoptotic susceptibility by inhibiting the cytochrome c-dependent apoptotic pathway in human colon cancer cells. Cancer Res., 62: 6323-6328, 2002.
8. Hsu, A-L., Ching, T-T., Wang, D-S., Song, X., Rangnekar, V. M., and Chen, C-S. The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J. Biol. Chem., 275: 11397-11403, 2000.
9. Lin, M-T., Lee, R-C., Yang, P-C., Ho, F-M., and Kuo, M-L. Cyclooxygenase-2 inducing Mcl-1-dependent survival mechanism in human lung adenocarcinoma CL1.0 cells. J. Biol. Chem., 276: 48997-49002, 2001.
10. Tang, Q., Gonzales, M., Inoue, H., and Bowden, G. T. Roles of Akt and glycogen synthase 3β in the ultraviolet B induction of cyclooxygenase-2 transcription in human keratinocytes. Cancer Res., 61: 4329-4332, 2001.
11. Yamazaki, R., Kusunoki, N., Matsuzaki, T., Hashimoto, S., and Kawai, S. Selective cyclooxygenase-2 inhibitors show a differential ability to inhibit proliferation and induce apoptosis of colon adenocarcinoma cells. FEBS Lett., 531: 278-284, 2002.
12. Simeone, A., Ekmekcioglu, S., Broemeling, L. D., Grimm, E. A., and Tari, A. M. A novel mechanism by which N-(4-hydroxyphenyl)retinamide inhibits breast cancer cell growth: the production of nitric oxide. Mol. Cancer Ther., 1: 1009-1017, 2002.
13. Formelli, F., Clerici, M., Campa, T., Di Mauro, M., Mascotti, G., Moglia, D., De Palo, G., Costa, A., and Veronesi, U. J. Five-year administration of fenretinide: pharmacokinetics and effects on plasma retinol concentrations. Clin. Oncol., 11: 2036-2042, 1993.
14. Hawk, E. T., Viner, J. L., Dannenberg, A., and DuBois, R. N. COX-2 in cancer - a player that's defining the rules. J. Natl. Cancer Inst., 94: 545-546, 2002.
15. Witters, L. M., Kumar, R., Chinnchilli, V. M., and Lipton, A. Enhanced anti-proliferative activity of the combination of tamoxifen plus Her-2-neu antibody. Breast Cancer Res. Treat., 42: 1-5, 1997.
16. Mann, M., Sheng, H., Shao, J., Williams, C. S., Pisacane, P. I., Sliwkowski, M. X., and DuBois, R. N. Targeting cyclooxygenase-2 and HER-2/neu pathways inhibits colorectal carcinoma growth. Gastroenterology, 120: 1713-1719, 2001.
17. Harries, M., and Smith, I. The development and clinical use of tmstuzumab (Herceptin). Endocrine-Rel. Cancer (Phila.), 9: 75-85, 2002.
18. Howe, L. R., Subbaramaiah, K., Patel, J., Masferrer, J. L., Deora, A., Hudis, C., Thaler, H. T., Muller, W. J., Du, B., Brown, A. M. C., and Dannenberg, A. J. Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancer. Cancer Res., 62: 5405-5407, 2002.
19. Veronesi, U., De Palo, G., Marubini, E., Costa, A., Formelli, F., Mariani, L., Decensi, A., Camerini, T., Del Turco, M. R., Di Mauro, M. G., Muraca, M. G., Del Vecchio, M., Pinto, C., D'Aiuto, G., Boni, C., Campa, T., Magni, A., Miceli, R., Perloff, M., Malone, W. F., and Sporn, M. B. Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer. J. Natl. Cancer Inst., 91: 1847-56, 1999.